Loading
A change on the heart's electrical trace, caused by some drugs blocking a potassium channel (hERG), that in rare cases sets off a dangerous rhythm. Drugs that do this need ECG checks and care with other medicines and low potassium or magnesium.
Off-target hERG inhibition is common among kinase inhibitors (vandetanib, nilotinib, ribociclib, osimertinib, mobocertinib, selpercatinib, ivosidenib) and other drugs (arsenic trioxide, ondansetron, methadone); labels require baseline and periodic ECGs and electrolyte correction, and combining QT-prolonging drugs is avoided. Clinically important arrhythmia is rare, but QT prolongation has delayed or narrowed approvals and is screened for in early drug development (thorough QT studies). A QTc above 500 ms or an increase over 60 ms usually triggers dose interruption.
Showing the molecule this term concerns: Nilotinib.
Shares Cardiotoxicity (LVEF decline, cardiomyopathy), Troponin and natriuretic peptide monitoring during cancer treatment.
Shares Cardiotoxicity (LVEF decline, cardiomyopathy), Troponin and natriuretic peptide monitoring during cancer treatment.
Shares Nilotinib, Tyrosine kinase inhibitor (TKI).
Shares Cardiotoxicity (LVEF decline, cardiomyopathy), Troponin and natriuretic peptide monitoring during cancer treatment.